Healthcare
Live Price
Offline$15.63
+0.00% today
Window Change
-11.75%
Window
May 29, 2026 → Jun 12, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars · May 29, 2026 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
WuXi AppTec Co., Ltd. (WUXIF) is a Healthcare stock with a market cap of $270.95B and listed on OTC. The stock last traded around $15.63 and down 11.8% across the available one-year price window (May 29, 2026 → Jun 12, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of +104.3%, a dividend yield of 1.5%. What stands out right now is revenue +15.8%, EPS +104.3%, free cash flow +38.8% with operating margin 42.7% and ROIC 17.5%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.9 and price/sales 5.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines WUXIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WUXIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WUXIF Max Drawdown
-18.56%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WUXIF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.9B
-41.8% YoY
FY Net Income
$5.1B
-42.2% YoY
Free Cash Flow
-$2.3B
-460.9% YoY
Revenue Growth
+15.8%
EPS Growth
+104.3%
Gross Margin
49.2%
Net Margin
41.7%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 45.5B | 39.2B | 40.3B | 39.4B | 22.9B |
| Gross Profit | 21.7B | 16.3B | 16.6B | 14.7B | 8.3B |
| Operating Income | 17.0B | 11.6B | 11.9B | 10.7B | 6.0B |
| EBITDA | 27.7B | 14.5B | 14.2B | 12.4B | 7.4B |
| Net Income | 19.2B | 9.5B | 9.6B | 8.8B | 5.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.1B | 18.3B | 13.8B | 8.0B | 8.2B |
| Total Assets | 103.1B | 80.3B | 73.7B | 64.7B | 55.1B |
| Total Liabilities | 22.9B | 21.2B | 18.2B | 17.8B | 16.4B |
| Shareholder Equity | 79.7B | 58.6B | 55.1B | 46.6B | 38.5B |
| Total Debt | 8.3B | 4.7B | 5.5B | 5.9B | 4.3B |
| Net Debt | -26.9B | -13.6B | -8.0B | -2.1B | -4.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4.6B
-56.8% YoY
Capital Expenditures
6.9B
+30.4% YoY
Free Cash Flow
2.3B
-460.9% YoY
Key ratios
Gross Margin
49.2%
Operating Margin
42.7%
Net Margin
41.7%
ROE
27.3%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.